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Background: Unresectable colorectal cancer has a poor prognosis. However, some patients survive intensive
chemotherapy, and complete resection of primary and metastatic tumors may even be possible. In the present
study, we examined the prognostic factors associated with survival after intensive chemotherapy in patients with
unresectable colorectal cancer.
Methods: This retrospective study enrolled 61 patients diagnosed with unresectable locally advanced colorectal
cancer between January 2004 and December 2013. Among the prognostic parameters, we found that the
prognoses of patients with abnormal performance status (PS) of 2 or 3, high Glasgow Prognostic Score (GPS) of 1
or 2, high neutrophil/lymphocyte ratio (NLR) >5, and low prognostic nutritional index (PNI) <40 were poor. Thus, we
scored each patient according to our scoring system (abnormal PS, 2 or 3 = +1; high GPS, 1 or 2 = +1; high NLR, >5 = +1;
and low PNI, <40 = +1). If the patient showed abnormalities in every parameter, the score would be +4.
Results: Sixteen patients had a score of 0, 17 scored +1, 10 scored +2, 17 scored +3, and one scored +4. The median
survival time (MST) of the 61 patients was 9 months. Patients were divided into two groups, a low-score group (0 and +1)
and a high-score group (+2, +3, and +4). The MST of the 33 patients in the low-score group was significantly longer than
that of the 28 patients in the high-score group (15 months versus 4 months, P < 0.001). Also, conversion chemotherapy
was performed in 4.9% (3/61) of patients. And these 3 patients were in a low-score group.
Conclusions: This new prognostic scoring system may help to select patients with unresectable advanced colorectal
cancer who are able to survive through intensive chemotherapy.
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Unresectable locally advanced colorectal cancer has a
poor prognosis. Many patients suffer from obstructive
ileus or sub-ileus, and bypass surgery or artificial anus
reconstruction may be needed to improve their quality
of life. 5-Fluorouracil in combination with leucovorin plus
oxaliplatin or irinotecan, with or without molecularly tar-
geted drugs, has been administered as first-line and as the
standard treatment for patients with unresectable colorec-
tal cancer [1,2]. Many patients fail to recover from such
palliative surgery and effective chemotherapy is therefore
not possible. However, some patients undergo complete* Correspondence: masaike@med.tottori-u.ac.jp
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unless otherwise stated.resection of primary and metastatic cancer sites after inten-
sive chemotherapy, and may subsequently survive for long
periods. It is therefore important to identify those patients
who are able to survive through intensive chemotherapy.
Eastern Cooperative Oncology Group Performance
Status (ECOG-PS) has been recognized as a good indicator
for the use of intensive chemotherapy in advanced car-
cinoma [3,4]; however, this parameter lacks objectivity.
The Glasgow Prognostic Score (GPS) has been shown
to improve the accuracy of predicting cancer-specific
survival in a variety of common solid tumors, including
colorectal cancer [5,6]. Regarding measurement of the
systemic inflammatory response, the combination of
C-reactive protein (CRP) and albumin (ALB) may be
useful for diagnosing not only chronic inflammationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Clinicopathological characteristics of 61 patients
Age (years, mean ± SD (median and range)) 67.8 ± 13.5 (68, 35-94)
Gender (male/female) 35/26




Primary tumor-related obstruction (yes/no) 36/25
Metastasis (n)
Liver only 20
Liver and lung 10
Liver and peritoneum 5




Lung and bone 1
Treatment (n)
Chemotherapy only 16
Surgical intervention + chemotherapy 25
Surgical intervention only 13
Best supportive care 7
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colleagues [7] and Yamanaka and colleagues [8] concluded
that the neutrophil/lymphocyte ratio (NLR) in the periph-
eral blood of patients was one aspect of the chronic
systemic inflammatory response that influenced clinical
outcomes in patients with colorectal cancer, while Ubukata
and colleagues [9] reported that elevated NLR indicated an
immunosuppressive state in cancer patients. NLR in per-
ipheral blood may thus be considered as both a marker of
inflammation and also an immunological marker. Preopera-
tive assessment of a patient’s immunological and nutritional
conditions (prognostic nutritional index, or PNI) has re-
cently been reported as an important marker in cancer
patients [10,11]. Furthermore, serum carcinoembryonic
antigen (CEA) level is known to be a good indicator for
progression of colorectal cancer [12].
In the present study, we evaluated the objective prog-
nostic markers GPS, NLR, PNI, and CEA in consecutive
patients with unresectable advanced colorectal cancer
and investigated whether these markers predicted response
to chemotherapy and long-term survival.
Methods
Patients
A total of 615 primary colorectal cancer patients were
introduced to our department for medical treatment be-
tween January 2004 and December 2013. Primary colorec-
tal regions had been resected in 550 patients (89.4%), but
colorectal resection had been abandoned in the remaining
65 patients (10.6%) because of advancement of primary
or metastatic tumors, poor performance status (PS), or
advanced age. Of these 65 patients, four with no ad-
vancement of tumors who refused further treatment
were excluded from this study. Sixty-one patients with lo-
cally advanced colorectal cancer with invasion to neighbor-
ing important organs (such as the liver, pancreas, kidney,
bladder, or sacral bone) with or without synchronous dis-
tant metastasis were diagnosed as initially unresectable.
Local invasion of tumors were detected to cavitas pelvis in-
cluding sacral bone in 19, to liver, duodenum, and pancreas
in 11, to uterus or bladder in 18, and to kidney or ureter in
13 patients. Other clinicopathological characteristics of
the 61 patients are shown in Table 1. Obstruction was the
most commonly detected primary tumor-related symptom
(obstruction, 30; bleeding or anemia, 5; obstruction and
bleeding, 6; and local pain, 4). The 36 patients (59%) with
obstruction caused by primary tumors underwent bypass
surgery (n = 8), artificial anus reconstruction (n = 26),
or both (n = 2). Metastases were found in 46 patients
(75.4%), with liver metastasis the most frequently detected.
No distant metastases were found in 15 patients.
Chemotherapy and chemo-radiotherapy with or without
surgical intervention were performed in 41 patients (67.2%;
chemotherapy only, n = 32; and chemo-radiotherapy, n = 9),but no effective treatment other than surgery was possible
in a further 13 patients. Seven patients with advanced age
or poor PS received best supportive care. The 61 patients
were followed until May 2014 and the median follow-up
time was 8 months.
Blood samples
Blood samples were taken from each patient routinely at
their first visit to our hospital. CRP, serum ALB, NLR,
PNI, and CEA levels were analyzed for each patient.
Scoring system
Patients were scored according to the original GPS. The
GPS consists of the combination of CRP and ALB mea-
surements. Patients with normal CRP (≤1.0 mg/dL) and
normal ALB (≥3.5 g/dL) had a GPS of 0 and were classified
as the low GPS group. Patients with either one abnormal
factor (GPS = 1), or both abnormal factors (GPS = 2) were
classified as the high GPS group. According to a previ-
ous report [7], an NLR ≥5 was considered abnormal.
The PNI was calculated using the following formula:
10 × serum ALB concentration (g/dL) + 0.005 × lymphocyte
count (number/mm2) in peripheral blood. The PNI cut-off
value was determined to be 40 [10]. According to Hsu and
colleagues [12], CEA ≥10 ng/mL was considered abnormal.
All investigations were conducted in conformity with
the Recommendations from the Declaration of Helsinki.
Informed consent was obtained from all these 61 patients
about their treatment. The study protocol has been
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Statistical analysis
Differences between two parameters were compared using
χ2 tests for independence, Fisher’s exact probability test, and
the Mann–Whitney U test. Spearman’s rank correlation
coefficient was used to assess the correlation between
two parameters. Survival rates were estimated by the
Kaplan-Meier method, and the significance of differences
between survival curves was examined by log-rank tests.
A P value <0.05 was regarded as statistically significant.
Results
The median survival time (MST) of the 61 patients was
9 months (range 1 to 75 months). Chemotherapy and
chemo-radiotherapy were performed in 41 patients;
however, chemotherapy was ceased after surgical interven-
tion in 13 patients because of poor PS or rapid tumor
growth after surgery (Table 1). The MST in the 41 patients
who underwent chemotherapy was significantly longer
than that of the remaining 20 patients (10 months ver-
sus 3 months, P = 0.006). To select those patients likely
to survive intensive treatment, we analyzed several
prognostic factors. Table 2 shows the correlations be-
tween several prognostic factors and patient survival.
According to our data, patient age, serum CEA level, and
location of tumors (data not shown) were not correlated
with patient survival.
The mean levels of CRP and ALB, lymphocyte count
in peripheral blood, NLR, PNI, and CEA in the 61 patients
were 3.2 (range 0.01 to 13.9) mg/dL, 3.4 (range 1.8 to 4.7)
g/dL, 1,322 (range 123 to 2,899)/mm2, 5.7 (range 1.1 to 31),
40.6 (range 19.6 to 58) and 567 (range 1.2 to 20,157)Table 2 Prognostic parameters in patients with
unresectable advanced colorectal carcinoma
n MST (months) P
Age (years) ≥75 22 9 0.303
<75 39 9
ECOG-PS 0 or 1 46 10 0.022
2 or 3 15 5
GPS 0 or 1 37 12 <0.001
2 24 4
NLR ≥5 29 4 0.002
<5 32 13
PNI ≥40 35 10 0.002
<40 26 4
CEA (ng/mL) ≥10 33 9 0.268
<10 28 9
CEA, carcinoembryonic antigen; ECOG-PS, Eastern Cooperative Oncology Group
Performance Status; GPS, Glasgow Prognostic Score; MST, median survival time;
NLR, neutrophil/lymphocyte ratio; PNI, prognostic nutritional index.ng/mL, respectively. Fifty-three patients died of progressive
disease during the follow-up period and the remaining
eight were alive at May 2014. Only one patient under-
went complete resection of both distant metastatic sites
(lung and liver) and the primary tumor after bypass sur-
gery followed by intensive chemotherapy, and this pa-
tient remained alive at 75 months after the initial visit to
our hospital, without recurrence or additional treatment.
Primary tumor resection was performed in a further two
patients, one of whom died at 35 months as a result of pro-
gression of liver metastasis, and the other remained alive at
13 months, with chemotherapy. Conversion chemotherapy
was therefore performed in 4.9% (3/61) of patients with ini-
tially unresectable locally advanced colorectal cancer.
Table 3 indicates our scoring system. According to our
scoring system, patients with abnormal PS, GPS, NLR,
and PNI had a score of 4. Sixteen patients scored 0, 17
scored +1, 10 scored +2, 17 scored +3, and 1 scored +4.
The 61 patients were divided into two groups based on
our scoring system: a low-score group (0 and +1) and a
high-score group (+2, +3, and +4). The MST of the 33 pa-
tients in the low-score group (15 months) was significantly
higher than that of the 28 patients in the high-score group
(4 months, P < 0.001; Figure 1). Three patients who under-
went conversion chemotherapy were in the low-score
group. Thus, these results indicate that this scoring system
based on a combination of several prognostic factors
may represent a useful method for selecting patients
with initially unresectable advanced colorectal cancer
who will survive.
Discussion
R0 (complete resection of tumors) surgery is the only
treatment associated with long-term survival in patients
with advanced colorectal cancer. However, this radical
surgery may have to be omitted because of numerous dis-
tant metastases or local advancement of tumors. Effective
chemotherapy should be administered and palliative
surgery (bypass surgery or artificial anus reconstruction)Table 3 Scoring system
n Score
ECOG-PS 0 or 1 46 0
2 or 3 15 +1
GPS 0 or 1 37 0
2 24 +1
NLR ≥ 5 29 +1
< 5 32 0
PNI ≥ 40 35 0
< 40 26 +1
ECOG-PS, Eastern Cooperative Oncology Group Performance Status; GPS,
Glasgow Prognostic Score; NLR, neutrophil/lymphocyte ratio; PNI, prognostic
nutritional index.
Figure 1 Survival curves of patients with a low- and high- score
groups. The survival curve of 33 patients with low scores (score 0
and +1; solid line) was significantly higher than that for 28 patients
with high scores (score +2, +3, and +4; dashed line; P < 0.001).
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unresectable at the time of administration (initially
unresectable colorectal cancer), complete resection of
both primary and metastatic tumors can be performed
after palliative surgery and intensive chemotherapy in
a few patients. Such conversion therapy has been asso-
ciated with favorable long-term survival in patients
with initially unresectable colorectal cancer [13-15]. In
the present study, we analyzed the factors used to esti-
mate who can undergo conversion therapy in patients
with locally advanced unresectable colorectal cancer
who had palliative surgery or chemotherapy.
Although conversion chemotherapy has been discussed
in relation to unresectable liver metastases, few studies have
considered conversion chemotherapy for locally advanced
colorectal cancer [16,17]. Hsu and colleagues [12] reported
that aggressive chemotherapy had a survival benefit, even
in patients with unresectable locally advanced colorectal
cancer. They concluded that high a CEA level was a prog-
nostic factor for poorer survival in these patients. In this
study, surgical resection of primary sites, or both primary
and metastatic sites, could be performed after intensive
chemotherapy in 5% of patients with initially unresectable
and locally advanced colorectal cancer. However, prior to
administering intensive chemotherapy and performing con-
version chemotherapy, it is necessary to identify those pa-
tients likely to survive. The CEA level is widely used to
monitor recurrence during postoperative follow-up, and
high serum CEA levels are associated with advanced tumor
stage, poor prognosis, and reduced survival in patients with
colorectal cancer. CEA may therefore be a good indicator
of tumor progression. However, in our study we found that
high serum CEA levels did not reflect survival of patients
with locally advanced colorectal cancer. Also, many reportssuggest that CEA levels did not correlate with tumor
progression in many colorectal tumors [10,11]. Thus,
we excluded the pretreatment serum CEA level from
our scoring system.
CRP, serum ALB, and peripheral lymphocyte count in
cancer patients have recently attracted research attention.
These factors may act as indicators of inflammation, nutri-
tion, and immunity. GPS is well known as an inflammatory
and nutritional prognostic parameter in various cancers,
and may be a useful marker for treatment administration
in advanced cancers [18,19]. Ikuta and colleagues [19] re-
ported that poor GPS may be a negative indicator for pal-
liative bypass surgery in unresectable pancreatic or biliary
cancers. NLR may also indicate the patient’s inflammation
and immunity status. Circulating lymphocytes are known
to play an important immunological role in various
carcinomas [20,21]. Additionally, a strong correlation
between cancer progression and lymphopenia was de-
tected in patients with clear cell renal carcinoma [22].
Lissoni and colleagues reported that lymphocytosis oc-
curred independently of tumor histotype and chemo-
therapeutic regimen in patients who achieved objective
tumor regression in response to chemotherapy, and that
the mean lymphocyte count was significantly increased
after chemotherapy [23]. They added that the mean
lymphocyte count decreased with chemotherapy in pa-
tients with tumor progression.
Furthermore, ECOG-PS and Onodera’s PNI are known
nutritional markers. Although both these markers may
be strong prognostic indicators, analyzing them separ-
ately may not be enough to select patients able to sur-
vive intensive treatment. We therefore advocated a new
scoring system using ECOG-PS, GPS, NLR, and PNI.
The MST in patients with low scores (score 0 or +1)
was 15 months, which was significantly longer than that
of patients with high scores (+2, +3, or +4; 4 months).
Although the sample size in this study was small, the
scoring system was able to predict the prognosis of
patients with unresectable advanced colorectal cancer
during treatment. In order to prove this fact, future
large-scale study is needed.
Conclusion
Patients with locally advanced colorectal cancer with
distant metastasis who have low scores may be able to
survive through intensive treatment, even if they were
deemed to be unresectable at the time of pretreatment.
The number of patients of our study was small, but the
results from our primitive study may lead us to large-scale
study in the future.
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